DRG Market Assessment 보고서

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key retinal vein occlusion patient populations covering 171 countries…

Gout is a painful, systemic inflammatory condition caused by elevated serum uric acid (sUA) and characterized by intermittent acute flares. Treatment of acute gout flares typically involves NSAIDs…

Clarivate Epidemiology’s coverage of osteopenia (OPE) comprises epidemiological estimates of key patient populations in seven emerging pharmaceutical markets. We report the prevalence of OPE for…

Clarivate Epidemiology’s coverage of osteopenia (OPE) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany…

Clarivate’s Epidemiology’s coverage of osteopenia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of osteopenia for each…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key OPE patient populations, covering 171 countries and more than 99% of…

The renal cell carcinoma (RCC) therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens…

Clarivate Epidemiology’s coverage of marginal zone lymphoma (MZL) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

Graft versus host disease (GVHD) is a potentially life-threatening complication of allogenic hematopoietic stem cell transplantation (HSCT). Steroids have been the first-line therapy for the…

Clarivate Epidemiology’s coverage of progressive supranuclear palsy (PSP) comprises epidemiological estimates of diagnosed prevalence in the major mature pharmaceutical markets of the United…

Many well-established therapies are available to treat ulcerative colitis (UC) in the EU5. TNF-alpha inhibitors (Janssen’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), and…

The treatment of adult psoriasis represents an increasingly lucrative market for biologics for moderate to severe disease, for which conventional systemic and topical treatments are not sufficient…